Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.

Andreassen, C; Rosenstein, B; Kerns, S; Ostrer, H; De Ruysscher, D; Cesaretti, J; Barnett, G; Dunning, A; Dorling, L; West, Catharine M L; Burnet, N; Elliott, R; Coles, C; Hall, E; Fachal, L; Vega, A; Gómez-Caamaño, A; Talbot, C; Symonds, R; De Ruyck, K; Thierens, H; Ost, P; Chang-Claude, J; Seibold, P; Popanda, O; Overgaard, M; Dearnaley, D; Sydes, M; Azria, D; Koch, C; Parliament, M; Blackshaw, M; Sia, M; Fuentes-Raspall, M; Ramon Y Cajal, T; Barnadas, A; Vesprini, D; Gutiérrez-Enríquez, S; Mollà, M; Díez, O; Yarnold, J; Overgaard, J; Bentzen, S; Alsner, J

Affiliation

Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark.

Issue Date

2016-07-18

Metadata

Show full item record

Abstract

Several small studies have indicated that the ATM rs1801516 SNP is associated with risk of normal tissue toxicity after radiotherapy. However, the findings have not been consistent. In order to test this SNP in a well-powered study, an individual patient data meta-analysis was carried out by the International Radiogenomics Consortium.

Citation

Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. 2016: Radiother Oncol

Journal

Radiotherapy and Oncology

URI

http://hdl.handle.net/10541/618573

DOI

10.1016/j.radonc.2016.06.017

PubMed ID

27443449

Type

Article

Language

ISSN

1879-0887

Collections

All Christie Publications